Recent study on dietary modifications and supplement use for endometriosis pain aimed to investigate the effectiveness of ...

Organon said on Wednesday it will the stop development of an experimental treatment it acquired through its purchase of Forendo Pharma, after the drug failed to reduce pelvic pain in women with ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health. New drugs for obesity ...

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational candidate OG-6219 in ...

Women with colorectal cancer appear to have higher risk for dyspareunia, pelvic inflammatory disease, endometriosis and ...

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

Endometriosis is an inflammatory illness that affects millions of women worldwide, causing excruciating pelvic pain, menstrual abnormalities, and infertility. While surgery offers a cure and ...

A recent study finds that a low FODMAP diet significantly reduces gastrointestinal symptoms in women with endometriosis, ...